LARAZOTIDE ACETATE - Research Grade Peptide

LARAZOTIDE ACETATE – Research-Grade Synthetic Octapeptide

For research purposes only. This product is supplied exclusively for scientific laboratory research and analytical purposes. It is not intended for human or animal use, consumption, clinical use or therapeutic application. It must not be used in any way that contravenes applicable laws or the requirements of the Medicines and Healthcare products Regulatory Agency.

• Research-grade synthetic octapeptide with batch documentation available where supplied
• Defined linear peptide sequence comprising eight amino-acid residues
• Supplied in the larazotide acetate chemical form where confirmed by the applicable batch Certificate of Analysis
• Supplied as lyophilised laboratory material in sealed flip-top headspace vials
• Batch identity, chromatographic purity, peptide content, acetate content and analytical specifications stated in the applicable Certificate of Analysis
• Handled and supplied exclusively as a research-use laboratory material

All of our research peptides and related laboratory materials are supplied strictly for scientific research and laboratory use only. Each vial contains lyophilised material prepared to support controlled laboratory handling and storage. The stated nominal amount refers to the declared Larazotide Acetate content of a single vial, subject to the applicable batch documentation and stated assay basis. Where dissolution or reconstitution is required, the solvent, buffer, concentration, handling procedure and storage conditions stated in the applicable Certificate of Analysis, Safety Data Sheet or validated laboratory method should be followed. We do not provide advice or recommendations concerning dosage, administration or use in humans or animals.

Chemical Information:

• Product Name: LARAZOTIDE ACETATE
• Preferred Substance Name: Larazotide acetate
• Alternative Names: AT-1001; Larazotide acetate salt; Larazotide monoacetate; Gly-Gly-Val-Leu-Val-Gln-Pro-Gly acetate
• Chemical Classification: Synthetic linear octapeptide acetate
• Sequence Length: Eight amino-acid residues
• Peptide Sequence: H-Gly-Gly-Val-Leu-Val-Gln-Pro-Gly-OH
• One-Letter Sequence: GGVLVQPG
• Sequence-Based Chemical Name: Glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolylglycine acetate
• N-Terminal Structure: Free glycine amino terminus
• C-Terminal Structure: Free glycine carboxylic acid terminus
• Larazotide Acetate CAS Number: 881851-50-9
• Larazotide Acetate PubChem Compound Identifier: CID 44146842
• Larazotide Acetate Unique Ingredient Identifier: FO8S2IW40N
• Larazotide Acetate Molecular Formula: C₃₄H₅₉N₉O₁₂
• Alternative Formula Presentation: C₃₂H₅₅N₉O₁₀ · C₂H₄O₂
• Larazotide Acetate Average Molecular Weight: Approximately 785.89 g/mol
• Larazotide Acetate Exact Mass: Approximately 785.4283 Da
• Reference Acetate Stoichiometry: The reference molecular formula represents one larazotide molecule associated with one acetic acid component
• Parent Larazotide CAS Number: 258818-34-7
• Parent Larazotide PubChem Compound Identifier: CID 9810532
• Parent Larazotide Unique Ingredient Identifier: ZN3R5560ZV
• Parent Larazotide Molecular Formula: C₃₂H₅₅N₉O₁₀
• Parent Larazotide Average Molecular Weight: Approximately 725.85 g/mol
• Physical Form: Lyophilised laboratory material, as stated in the applicable batch Certificate of Analysis
• Appearance: White to off-white laboratory material, subject to confirmation in the applicable batch Certificate of Analysis
• Purity Specification: The applicable chromatographic purity result, analytical method and acceptance criterion are stated in the batch Certificate of Analysis
• Peptide-Content Specification: Net larazotide content should be distinguished from chromatographic purity and interpreted alongside acetate, water and residual-solvent results
• Nominal Amount Basis: The applicable product specification should state whether the declared vial amount is calculated as total Larazotide Acetate material or as parent larazotide peptide equivalent
• Acetate-Content Specification: Measured acetate content and acetate-to-peptide ratio should be stated or supported by the applicable batch analytical documentation
• Chemical-Form Confirmation: The applicable Certificate of Analysis should confirm that the supplied material is Larazotide Acetate rather than uncountered larazotide, a sodium salt or another counter-ion form
• Identity Confirmation: Product identity should be supported by sequence documentation and mass-spectrometry results consistent with the specified larazotide octapeptide
• Endotoxin Specification: The applicable bacterial endotoxin or LPS result, analytical method, reporting units and acceptance limit should be stated in the batch Certificate of Analysis
• Analytical Interpretation: Molecular identity, amino-acid sequence, chromatographic purity, net peptide content, acetate content, water content, residual solvents and bacterial endotoxin results are separate analytical measurements and should be interpreted together

✓ Batch documentation – Completed Certificate of Analysis documentation is provided where supplied for review.
✓ Certificate of Analysis – Accessible through the product QR code where provided for the applicable batch.
✓ Safety Data Sheet – Supplied to support appropriate laboratory handling, storage and regulatory compliance.
✓ Sequence documentation – The eight-residue amino-acid sequence and terminal structures should be confirmed using the applicable batch records.
✓ Mass-spectrometry documentation – Molecular identity should be supported by analytical mass data consistent with the specified Larazotide Acetate structure.
✓ Purity documentation – The reported chromatographic purity applies only to the analytical method and batch stated in the Certificate of Analysis.
✓ Peptide-content documentation – Net larazotide content should be distinguished from chromatographic purity and interpreted alongside acetate, water and residual-solvent results.
✓ Acetate-content documentation – Acetate identity, content and peptide-to-acetate ratio should be stated or supported where applicable.
✓ Chemical-form documentation – The acetate form, parent peptide or another counter-ion form should be identified clearly in the applicable product and batch records.
✓ Bacterial endotoxin documentation – The applicable bacterial endotoxin or LPS result should identify the test method, reporting units and acceptance criterion.
✓ Supplier documentation – Reviewed where supporting synthesis, purification and analytical records are supplied.
✓ Fast, reliable and trackable express delivery – Securely packaged and dispatched using insulated or temperature-managed packaging where required by the applicable transport and storage specification.

For Research Use Only
This product is supplied strictly for scientific research, laboratory analysis and experimental work. It is not intended for human consumption, animal use, clinical use, diagnostic use or any form of therapeutic application.

Larazotide Acetate Product Overview

Our Larazotide Acetate research-grade synthetic octapeptide is supplied for controlled scientific laboratory investigation, analytical method development, peptide characterisation, high-performance liquid chromatography assessment and mass-spectrometry workflows. The material comprises a defined linear sequence of eight amino-acid residues with a free glycine amino terminus and a free glycine carboxylic acid terminus.

The material is handled with a focus on batch traceability, documented quality control and consistent laboratory presentation. Product identity, amino-acid sequence, terminal structure, chromatographic purity, net peptide content, acetate content, molecular form, water content, residual solvents, bacterial endotoxin results and other analytical specifications should be confirmed using the applicable batch Certificate of Analysis. Chromatographic purity should not automatically be interpreted as equivalent to the total net peptide content of the vial.

The CAS number 881851-50-9, molecular formula C₃₄H₅₉N₉O₁₂ and average molecular weight of approximately 785.89 g/mol describe the reference Larazotide Acetate form containing one acetic acid component. The parent uncountered larazotide peptide has a different CAS number, molecular formula and molecular weight. The applicable batch documentation should therefore identify the chemical form and whether the stated vial content is expressed as total acetate material or parent peptide equivalent.

For the majority of routine analytical, investigative and general laboratory work, the Regular Larazotide Acetate specification remains highly suitable. The premium black-and-gold ULTIMATE Larazotide Acetate option provides an additional preparative high-performance liquid chromatography purification stage and a more stringent bacterial endotoxin and lipopolysaccharide testing specification for scientific projects requiring enhanced quality-control parameters.

View Certificate of Analysis

View Safety Data Sheet